FINAL PROGRAM - EpiSouth

More documents

Recommendations

Info

Session 40 14th International Congress on Infectious Diseases Room Orchid B/C/D ~ Terrace Level Thursday, March 11, 2010 Oral Presentations Hyatt Regency Miami 10:15–12:15 VIRAL DISEASES 40.008 Risk of being seropositive for multiple HPV types among Finnish and Ugandan women P. B. Namujju 1 , H.-M. Surcel 1 , P. Koskela 1 , E. K. Mbidde 2 , M. Muwanga 2 , R. Byaruhanga 3 , C. Banura 3 , M. Kaasila 1 , R. Kirnbauer 4 , M. Lehtinen 5 1 Oulu (Finland), 2 Entebbe (Uganda), 3 Kampala (Uganda), 4 Vienna (Austria), 5 Tampere (Finland) 40.009 A phase 3 study of a short, two dose regimen of an investigational Hepatitis B vaccine J. Martin 1 , S. Halperin 2 , F. Diaz-Mitoma 3 1 Berkeley, CA (USA), 2 Halifax, NS (Canada), 3 Ottowa, ON (Canada) THURSDAY • March 11, 2010 104 ~ Final Program
Session 41 14th International Congress on Infectious Diseases South Hall ~ Lobby Level Thursday, March 11, 2010 Symposium Hyatt Regency Miami 10:15–12:15 CME CARBAPENEMASE-PRODUCING BACTERIA: THE THREAT OF ‘PANRESISTANCE’ Co-Chairs: Daniel LEW, Switzerland Po-Ren HSUEH, Taiwan 41.001 Detecting carbapenemase producers in the clinic C. Giske Stockholm (Sweden) 41.002 Clinical impact and current epidemiology of carbapenemase producers K. Thomson Omaha, NE (USA) 41.003 Controlling the spread of carbapenemase-producing bacteria M. Schwaber Tel Aviv (Israel) 41.004 Treatment options for carbapenenam-resistant infections G. Daikos Athens (Greece) Organized in collaboration with the International Society of Chemotherapy (ISC) THURSDAY • March 11, 2010 Final Program ~ 105
Page 1 and 2:
14th International Congress on Infe
Page 3 and 4:
Page 5 and 6:
ii ~ Final Program 14th Internation
Page 7 and 8:
Introduction by ISID 14th Internati
Page 9 and 10:
Introduction by SLAMVI 14th Interna
Page 11 and 12:
Congress Committees International O
Page 13 and 14:
International Society for Infectiou
Page 15 and 16:
Awards 14th International Congress
Page 17 and 18:
Acknowledgements 14th International
Page 19 and 20:
General Information 14th Internatio
Page 21 and 22:
Poster Presentations 14th Internati
Page 23 and 24:
Plenary Lectures 14th International
Page 25 and 26:
Plenary Lectures 14th International
Page 27 and 28:
Commercial Exhibition 14th Internat
Page 29 and 30:
Page 31 and 32:
Lobby Level James L. Knight Center
Page 33 and 34:
Meet-the-Expert 14th International
Page 35 and 36:
Session 2 14th International Congre
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43:
Meet-the-Expert Room Jasmine ~ Terr
Page 46 and 47:
Session 10 14th International Congr
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 57 and 58: Session 20 14th International Congr
Page 99: Session 34 14th International Congr
Page 114: Session 46 14th International Congr
Page 153 and 154: Meet-the-Expert Room Jasmine ~ Terr
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Faculty Disclosures 14th Internatio
Page 215 and 216:
Faculty Disclosures 14th Internatio
Page 217 and 218:
Authors Index 14th International Co
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
A Decade of Experience With PCV7: H
show all

FINAL PROGRAM - EpiSouth

Create successful ePaper yourself

Delete template?

Save as template?